Product Information
ORPHENADRINE 60 MG/2 ML VIAL is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $7.0744 per ML under NDC 00641618225. Its NADAC has been published 33 times since Feb 18, 2026.
FDA first approved this application on Mar 4, 2003. Its Orange Book therapeutic-equivalence code is AP.
Strength
60 mg/2mL
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00641618225
Classification
Generic
Dosage Form
INJECTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
7/22/2026
Active Ingredients
ORPHENADRINE CITRATEApproval Type
Generic (ANDA)
FDA Application
ANDA040463FDA Approved
3/4/2003
TE Code
AP
On Market Since
4/28/2003
Pharmacological Classes
Price Statistics
The NADAC for ORPHENADRINE 60 MG/2 ML VIAL has been published 33 times since Feb 18, 2026, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.0744 per ML |
|---|---|
| All-time high | $7.0744 (Sep 30, 2026) |
| All-time low | $7.0744 (Feb 18, 2026) |
| 52-week high | $7.0744 |
| 52-week low | $7.0744 |
| Median price | $7.0744 |
| Average price | $7.0744 |
| Largest weekly change | 0.0% (Feb 25, 2026) |
| Weeks tracked | 33 |
| Tracking since | Feb 18, 2026 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Orphenadrine citrate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Orphenadrine citrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Muscle Relaxant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ORPHENADRINE 60 MG/2 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for ORPHENADRINE 60 MG/2 ML VIAL, manufactured by Hikma Pharmaceuticals USA Inc., is $7.0744 per ML (NDC 00641618225), effective Sep 30, 2026.
How has the price of ORPHENADRINE 60 MG/2 ML VIAL changed over time?
Over the history we have for it, the NADAC for ORPHENADRINE 60 MG/2 ML VIAL has held within roughly two percent of its current level. It has been tracked across 33 weekly CMS publications since Feb 18, 2026.
What are the highest and lowest recorded NADAC prices for ORPHENADRINE 60 MG/2 ML VIAL?
Since Feb 18, 2026, the NADAC for ORPHENADRINE 60 MG/2 ML VIAL has ranged from a low of $7.0744 (Feb 18, 2026) to a high of $7.0744 (Sep 30, 2026), with a median of $7.0744 per ML.
Are there cheaper alternatives to ORPHENADRINE 60 MG/2 ML VIAL?
No other NADAC-published product currently shares the active ingredient and strength of ORPHENADRINE 60 MG/2 ML VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ORPHENADRINE 60 MG/2 ML VIAL?
ORPHENADRINE 60 MG/2 ML VIAL (NDC 00641618225) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.